Bicycle Therapeutics Plc (NASDAQ: BCYC) has caught the attention of the investment community today with its bullish price action. The company’s shares are currently up 4.17% on the day to $23.97.
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company’s oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009.
So far today, approximately 58,839 shares of Bicycle Therapeutics Plc have been exchanged, as compared to an average 30-day volume of 227.57k shares.
Bicycle Therapeutics Plc share prices have moved between a 52-week high of $33.49 and a 52-week low of $12.08. The stock has moved 5.84% over the past week.
To learn more about Bicycle Therapeutics Plc, visit the company’s website at https://www.bicycletherapeutics.com.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
IBN consists of financial brands introduced to the investment public over the course of 17+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.
Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.
For more information, please visit https://www.InvestorBrandNetwork.com